Biogen Idec Inc. said the Food and Drug Administration has agreed to review its experimental drug Eloctate as a treatment for hemophilia A. It would be injected once or twice a week; existing treatments are taken three or four times a week. Hemophilia A, which is inherited, occurs in one of 5,000 male births. Those with the disease don’t have enough factor VIII, a blood clotting protein. The FDA in March started reviewing Biogen Idec’s Alprolix for hemophilia B, which is even rarer and caused by a different deficiency.
FDA reviews Biogen’s hemophilia A drug
May 14, 2013
Read it all, now.
Don't miss any of your favorite stories again. Read the stories that matter to you as much as you want, whenever you want when you subscribe to BostonGlobe.com.
Get full access today for just 99¢